SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients
Key Points
- SARS-CoV-2 vaccines are generally safe in patients with pre-existing ITP but thrombocytopenia exacerbation may occur and requires monitoring
- Splenectomy and past use of 5 or more therapies predict higher risk of worsening thrombocytopenia in ITP patients post-SARS-CoV-2 vaccine